A first-in-human Phase 1 clinical trial conducted by researchers at the Cleveland Clinic has found that a single infusion of an experimental CRISPR-Cas9 gene-editing therapy produced lasting, significant reductions in LDL, or "bad," cholesterol and triglycerides in patients suffering from lipid disorders that had failed to respond adequately to conventional medications.
The landmark study followed a cohort of 15 patients over a full one-year period to determine whether the dramatic cholesterol and triglyceride reductions that were initially observed and reported after just two months would prove durable over time. The results, which mark a major milestone in the medical application of genetic engineering, showed that the beneficial effects not only persisted but remained stable throughout the 12-month evaluation window. Specifically, participants who received the highest dose of the therapy experienced a remarkable 52.5% reduction from their baseline measurements in low-density lipoprotein (LDL) cholesterol, alongside a 47.8% drop in circulating triglycerides.
Importantly, the clinical trial reported no serious adverse events related to the gene-editing therapy during the entire one-year follow-up period, offering an encouraging safety profile for a technology that permanently alters human DNA.
The groundbreaking findings were presented at the 2026 European Society of Cardiology annual meeting and were published simultaneously in the prestigious New England Journal of Medicine, signaling intense interest from the global cardiovascular research community.
"Building upon the initial data presented in November 2025, the durability of the lipid-lowering effect was impressive," said Cleveland Clinic cardiologist Luke Laffin, M.D., who served as the first author of the study. "It is encouraging that there were no serious safety events related to CTX310 in the trial and in the year following treatment. We look forward to continuing to investigate this therapy in a larger number of patients."
CRISPR-Cas9 represents a revolutionary gene-editing technology that is fundamentally designed to make highly targeted changes to specific, predetermined parts of a person’s DNA code. For years, scientists and medical researchers have been studying the platform as a potential paradigm-shifting way to treat serious, otherwise intractable diseases by directly altering the underlying genes that contribute to those conditions, rather than merely managing symptoms with daily medications.
Cholesterol Reductions Lasted for a Year
The journey from initial laboratory discoveries to human clinical trials has moved swiftly in recent years, but verifying the long-term durability of these interventions has remained a crucial hurdle. For patients with severe lipid disorders, standard therapies such as statins, ezetimibe, or PCSK9 inhibitors often fail to bring high-risk blood lipids down to safe levels, leaving individuals vulnerable to recurrent cardiovascular events, atherosclerosis, and premature heart disease.
The participants in the Cleveland Clinic trial represented this challenging patient demographic—individuals whose lipid abnormalities had proven resistant to standard-of-care medical management. By demonstrating that a single genetic intervention could alter lipid metabolism for an entire year without fading, the study offers a glimpse into a potential future where chronic conditions might be managed with one-time interventions rather than lifelong pharmaceutical regimens.
The positive reception at the European Society of Cardiology meeting underscores the medical community’s enthusiasm for therapies that can bypass patient non-compliance, which is a frequent obstacle in chronic cardiovascular disease management. Because a one-time infusion eliminates the need for daily pills or regular injections, it could fundamentally transform how medicine approaches genetic and metabolic drivers of heart disease. However, researchers emphasize that while the one-year data is a crucial stepping stone, much larger clinical trials will be necessary before the therapy can be considered for widespread clinical adoption.
How CTX310 Targets Blood Fats
The experimental treatment evaluated in the clinical trial is known as CTX310. Administered as a single intravenous infusion, the therapy is engineered to deliver the CRISPR-Cas9 gene-editing machinery specifically to the liver, which serves as the primary metabolic hub for processing fats and cholesterol in the human body.
Once inside the liver cells, the CRISPR system targets and deactivates a specific gene known as ANGPTL3 (angiopoietin-like 3). The ANGPTL3 protein normally plays a role in regulating the fats circulating in the bloodstream. By disabling this specific gene, the therapy effectively reduces the production and activity of the protein, which in turn leads to a pronounced reduction in both LDL cholesterol and triglycerides—two primary biomarkers heavily associated with the development and progression of cardiovascular disease.
Before receiving the CTX310 infusion, study participants were pre-treated with corticosteroids and antihistamines, a standard protocol in early-phase gene-editing trials designed to minimize potential immune reactions to the delivery mechanism or the editing components. Following the infusion, the research team closely monitored the participants to evaluate the overall safety of the treatment while systematically measuring changes in ANGPTL3 protein levels, LDL cholesterol concentrations, and triglyceride levels over time.
By the end of the 12-month monitoring window, the data revealed that patients who received the highest dose tier experienced an average reduction of approximately 50% in both LDL cholesterol and triglycerides. This consistent dual-action reduction is particularly significant because elevated levels of both lipid types severely compound a patient’s long-term cardiovascular risk.
Long-Term Monitoring Will Continue
Despite the enthusiasm surrounding the 12-month outcomes, researchers are exercising appropriate scientific caution. CTX310 remains strictly an experimental therapy, and the Phase 1 trial was intentionally small, involving just 15 participants designed primarily to evaluate initial safety, tolerability, and pharmacodynamic responses.
Because gene-editing therapies introduce permanent modifications to human biological systems, regulatory agencies maintain rigorous oversight regarding long-term patient safety. In accordance with guidelines established by the U.S. Food and Drug Administration (FDA) for gene-editing clinical trials, the participants in this study will continue to be monitored for long-term safety and health outcomes for a total of 15 years. This extended observation period is designed to detect any delayed or unforeseen adverse effects that might emerge years down the line.
The clinical trial was funded by CRISPR Therapeutics AG, based in Zug, Switzerland, the biotechnology company that developed the CTX310 therapy. Additionally, Dr. Laffin’s institution has received research funding from CRISPR Therapeutics to support ongoing scientific investigations into advanced genetic medicines. As the research transitions toward larger Phase 2 and eventual Phase 3 clinical trials, the medical community will be watching closely to see if these promising early results can be successfully replicated in broader, more diverse patient populations.